공지 : 도쿄증권거래소 JASDAQ 스탠다드 시장 신규 상장 관련 안내

Global Information
회사소개 | 문의 | 비교리스트

건선 치료제 시장 : 성장, 동향, COVID-19의 영향, 예측(2021-2026년)

Psoriasis Drugs Market - Growth, Trends , COVID-19 Impact , and Forecasts (2021 - 2026)

리서치사 Mordor Intelligence Pvt Ltd
발행일 2021년 03월 상품 코드 391446
페이지 정보 영문
가격
US $ 4,250 ₩ 4,793,000 PDF (Single User License)
US $ 4,750 ₩ 5,357,000 PDF (Team License: Up to 7 Users)
US $ 6,000 ₩ 6,766,000 PDF (Site License)
US $ 7,500 ₩ 8,458,000 PDF (Corporate License)


건선 치료제 시장 : 성장, 동향, COVID-19의 영향, 예측(2021-2026년) Psoriasis Drugs Market - Growth, Trends , COVID-19 Impact , and Forecasts (2021 - 2026)
발행일 : 2021년 03월 페이지 정보 : 영문

본 상품은 영문 자료로 한글과 영문목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문목차를 참고해주시기 바랍니다.

세계의 건선 치료제(Psoriasis Drugs) 시장에 대해 조사했으며, 시장 기회와 동향, 성장 촉진요인 및 저해요인, 치료법·작용기서·투여 경로·지역별 시장 분석, 경쟁 상황, 주요 기업 개요 등의 정보를 제공합니다.

목차

제1장 서론

  • 조사 성과
  • 조사 가정
  • 조사 범위

제2장 조사 방법

제3장 주요 요약

제4장 시장 역학

  • 시장 개요
  • 성장 촉진요인
  • 성장 저해요인
  • Porter's Five Forces 분석
    • 신규 참여업체의 위협
    • 바이어/소비자의 협상력
    • 공급업체의 협상력
    • 대체 제품의 위협
    • 업계내의 경쟁

제5장 시장 세분화

  • 치료법별
    • 생물제제
    • 저분자 전신성 의약품
    • 국소요법
  • 작용기서별
    • TNF 알파 억제제
    • PDE4 억제제
    • 인터류킨 억제제
    • 기타
  • 투여 경로별
    • 경구
    • 비경구
    • 국소
  • 지역별
    • 북미
    • 유럽
    • 아시아태평양
    • 중동 및 아프리카
    • 남미

제6장 경쟁 상황

  • 기업 개요
    • Eli Lilly and Company
    • Pfizer Inc.
    • Johnson and Johnson(Janssen Biotech Inc.)
    • Celgene Corporation
    • Takeda Pharmaceutical Company Limited
    • Stiefel Laboratories Inc.
    • Novartis AG
    • Amgen Inc.
    • Biogen Idec
    • AbbVie Inc.

제7장 시장 기회 및 향후 동향

KSM 19.11.05

The psoriasis drugs market was valued at USD 13,418 million in 2020 and is expected to reach USD 23,628 million in 2026, by registering a CAGR of 9.89%

The COVID-19 initially had a negative growth impact on the psoriasis market mainly because of the guidelines published by various regulatory bodies suggesting that patients receiving psoriasis treatment are at more risk of infecting with COVID-19. In March 2020, The International Psoriasis Council (IPC) recommends physicians discontinue or postpone the prescription of immunosuppressant medications. However later in September 2020, Researchers from the Perelman School of Medicine at the University of Pennsylvania and 16 other research institutions from the United States and Canada in collaboration with the National Psoriasis Foundation have created guidelines for caring for patients with Psoriasis during the coronavirus pandemic. The scientist finds no evidence that medical interventions to treat psoriasis and psoriatic arthritis should be interrupted or altered to minimize COVID-19 risks. This guideline is further expected to resume market growth.

An increasing disease burden and demand for psoriasis medicines in emerging economies and the increase in psoriasis research and pipeline drugs are the major factors responsible for the growth of the market.Novel drugs with oral administration open avenues for needle-averse patients. For instance, Bristol Myers Squibb currently has oral TYK2 inhibitor BMS-986165 , the efficacy of has been found similar to TNF-alpha inhibitors, this should be a driving factor for better uptake among patients averse to injectables

Also, in February 2019, Janssen Biotech, Inc., a biotechnology company received United States Food and Drug Administration approved TREMFYA, for the treatment of severe plaque psoriasis. In addition key players in the market are involved in various business strategies such as product launches, in order to expand product portfolio and have a competitive edge in the market. For instance, in October 2018, Sun Pharmaceuticals Industries Ltd announced the launch of 'Ilumya', a novel plaque psoriasis treatment drug in the market. Owing to the above-mentioned factors the market is expected to have a high growth rate during the forecast period. However, adverse side effects of most of the existing medication and the high cost of the treatment are the factors that are expected to hamper the market growth.

Key Market Trends

Interleukin Inhibitors is Expected to Grow with a High CAGR in the Forecast Period

Interleukin inhibitors are anticipated to witness the fastest growth during the forecast period. The factors aiding these interleukin inhibitors are their improved safety and efficacy when compared to other classes of psoriasis drugs which is consistently leading to increased adoption among patients. For instance, in 2019, the sales of Taltz has grown by 46% to USD 1,366.4 Million from USD 937.5 Million in 2018. Major approved antibodies targeting Interlunkins include Taltz (ixekizumab), Cosentyx (secukinumab), Siliq (brodalumab), Tremfya (guselkumab), Ilumya (tildrakizumab) and Skyrizi (risankizumab).

In March 2019, AbbVie Inc., one of the key players in the market received approval from the Japanese Ministry of Health Labour and Welfare (MHLW) for SKYRIZI (Risankizumab), an interleukin-23 (IL-23) inhibitor for treating plaque psoriasis, generalized pustular psoriasis, erythrodermic psoriasis, among others. The company has also received approval for SKYRIZI as a new treatment for plaque psoriasis in Europe in 2018. All these approvals in the market are further propelling the growth of the segment.

However, as psoriasis is a non-emergency condition, the ongoing COVID-19 pandemic has impacted the market as most of the interleukin R&D activities have been halted to focus on COVID-19 vaccine development.

North America Dominates the Market and is Expected to do so in the Forecast Period

North America is one of the worst affected regions by the ongoing COVID-19 pandemic. The growth of the psoriasis market is expected to slow down to some extent because patients are avoiding visiting dermatology clinics for psoriasis treatment Apart from restrictions on non-emergency medical services, new rules of the governments across this region have forced several players in the dermatology drug market to pause their business operations which have impacted the growth of the market.

North America is expected to dominate the psoriasis market during the forecast period. In North America, the United States holds the largest market share owing to the high prevalence of psoriasis. As per, Prevalence of Psoriasis in Children and Adolescents in the United States: A Claims-Based Analysis published in Feb. 2018, the prevalence of Psoriasis was estimated at 128 cases per 100,000 individuals. Other factors that will propel the market include the presence of favorable government initiatives, the presence of developed healthcare infrastructure, etc.

Owing to the increasing prevalence of the targeted disease and due to the wide acceptance in North American countries MC2 Therapeutics, a Europe-based company in August 2020 signed a Collaboration Agreement with EPI Health, LLC for commercialization of its WYNZORA Cream (calcipotriene and betamethasone dipropionate, w/w 0.005%/0.064%) in the United States market. The WYNZORA Cream was approved in July 2020, by the United States Food and Drug Administration (FDA) for the topical indication of plaque psoriasis in adults. The upcoming launch of WYNZORA Cream in the American market will further propel the market growth in this region.

Competitive Landscape

The psoriasis drugs market is moderately competitive and consists of several key players. With respect to the market share, few of the key players currently dominate the market. Companies are focusing on business expansion in developing regions or emerging markets, such as India, China, and South Korea, by adopting strategies, including alliances and acquisitions for the development of novel products. For instance, in August 2019, Amgen acquired Otezla, a biopharmaceutical company involved in the production of psoriasis drugs, a worth USD 13.40 billion. Also, in July 2019, Cipla entered into a partnership with Alvotech, a biopharmaceutical company to commercialize AVT02. AVT02 is an adalimumab biosimilar for plaque psoriasis and rheumatoid arthritis

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 Study Assumptions and Market Definition
  • 1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Increasing Disease Burden and Demand for Psoriasis Medicines in Emerging Economies
    • 4.2.2 Increasing Use of Combination Therapies
    • 4.2.3 Increase in Psoriasis Research and Pipeline Drugs
  • 4.3 Market Restraints
    • 4.3.1 Adverse Side Effects of Existing Medications
    • 4.3.2 High Cost of Psoriasis Treatments
    • 4.3.3 Extensive Drug Development and Approval Process
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 By Type of Treatment
    • 5.1.1 Biologic Drugs
    • 5.1.2 Small Molecule Systemic Drugs
    • 5.1.3 Tropical Therapies
  • 5.2 By Mechanism of Action
    • 5.2.1 TNF Alpha Inhibitors
      • 5.2.1.1 Etanercept
      • 5.2.1.2 Certolizumab Pegol
      • 5.2.1.3 Adalimumab
      • 5.2.1.4 Infiximab
      • 5.2.1.5 Golimumab
    • 5.2.2 PDE4 Inhibitors
      • 5.2.2.1 Apremilast
    • 5.2.3 Interleukin Inhibitors
      • 5.2.3.1 Secukinumab
      • 5.2.3.2 Ustekinumab
      • 5.2.3.3 Other Interleukin Inhibitors
    • 5.2.4 Other Mechanisms of Action
  • 5.3 By Route of Administration
    • 5.3.1 Oral
    • 5.3.2 Parenteral
    • 5.3.3 Topical
  • 5.4 Geography
    • 5.4.1 North America
      • 5.4.1.1 United States (By Type of Treatment, By Mechanism of Action, and By Route of Administration)
      • 5.4.1.2 Canada (By Type of Treatment, By Mechanism of Action, and By Route of Administration)
      • 5.4.1.3 Mexico (By Type of Treatment, By Mechanism of Action, and By Route of Administration)
    • 5.4.2 Europe
      • 5.4.2.1 Germany (By Type of Treatment, By Mechanism of Action, and By Route of Administration)
      • 5.4.2.2 United Kingdom (By Type of Treatment, By Mechanism of Action, and By Route of Administration)
      • 5.4.2.3 France (By Type of Treatment, By Mechanism of Action, and By Route of Administration)
      • 5.4.2.4 Italy (By Type of Treatment, By Mechanism of Action, and By Route of Administration)
      • 5.4.2.5 Spain (By Type of Treatment, By Mechanism of Action, and By Route of Administration)
      • 5.4.2.6 Rest of Europe (By Type of Treatment, By Mechanism of Action, and By Route of Administration)
    • 5.4.3 Asia-Pacific
      • 5.4.3.1 China (By Type of Treatment, By Mechanism of Action, and By Route of Administration)
      • 5.4.3.2 Japan (By Type of Treatment, By Mechanism of Action, and By Route of Administration)
      • 5.4.3.3 India (By Type of Treatment, By Mechanism of Action, and By Route of Administration)
      • 5.4.3.4 Australia (By Type of Treatment, By Mechanism of Action, and By Route of Administration)
      • 5.4.3.5 South Korea (By Type of Treatment, By Mechanism of Action, and By Route of Administration)
      • 5.4.3.6 Rest of Asia-Pacific (By Type of Treatment, By Mechanism of Action, and By Route of Administration)
    • 5.4.4 Middle East and Africa
      • 5.4.4.1 GCC (By Type of Treatment, By Mechanism of Action, and By Route of Administration)
      • 5.4.4.2 South Africa (By Type of Treatment, By Mechanism of Action, and By Route of Administration)
      • 5.4.4.3 Rest of Middle East and Africa (By Type of Treatment, By Mechanism of Action, and By Route of Administration)
    • 5.4.5 South America
      • 5.4.5.1 Brazil (By Type of Treatment, By Mechanism of Action, and By Route of Administration)
      • 5.4.5.2 Argentina (By Type of Treatment, By Mechanism of Action, and By Route of Administration)
      • 5.4.5.3 Rest of South America (By Type of Treatment, By Mechanism of Action, and By Route of Administration)

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 AbbVie Inc.
    • 6.1.2 Amgen Inc.
    • 6.1.3 AstraZenca
    • 6.1.4 Biogen Idec
    • 6.1.5 Boehringer Ingelheim
    • 6.1.6 Celgene Corporation
    • 6.1.7 Dr.Reddy`s Laboratories
    • 6.1.8 Eli Lilly and Company
    • 6.1.9 Forward Pharma
    • 6.1.10 Johnson and Johnson (Janssen Biotech Inc.)
    • 6.1.11 Leo Pharma A/S
    • 6.1.12 Merck and Co., Inc.
    • 6.1.13 Novartis AG
    • 6.1.14 Pfizer Inc.
    • 6.1.15 Stiefel Laboratories Inc.
    • 6.1.16 Stiefel Laboratories Inc.
    • 6.1.17 Sunpharmaceutical Industries Limited
    • 6.1.18 Takeda Pharmaceutical Company Limited
    • 6.1.19 UCB S.A.
    • 6.1.20 Valeant Pharmaceuticals

7 MARKET OPPORTUNITIES AND FUTURE TRENDS

Back to Top
전화 문의
F A Q